My bookmarksSign up free

2001/181/EC: Commission Decision of 22 February 2001 amending Annex I to Council Decision 91/666/EEC establishing Community reserves of foot-and-mouth disease vaccines and updating Decision 2000/112/EC with regard to distribution between antigen banks of antigen reserves (Text with EEA relevance) (notified under document number C(2001) 425)

2001/181/EC: Commission Decision of 22 February 2001 amending Annex I to Council Decision 91/666/EEC establishing Community reserves of foot-and-mouth disease vaccines and updating Decision 2000/112/EC with regard to distribution between antigen banks of antigen reserves (Text with EEA relevance) (notified under document number C(2001) 425)

Decision 91/666/EEC Β· Decision Β· 4 articles

Data as of 2026-07-04 Β· Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. Β· Read the official text β†—

Article 1

Annex I to Decision 91/666/EEC is replaced by Annex I to this Decision.

Article 2

The Annex to Decision 2000/112/EC is replaced by Annex II to this Decision.

Article 3

This Decision is addressed to the Member States. Done at Brussels, 22 February 2001. For the Commission David Byrne Member of the Commission (1) OJ L 368, 31.12.1991, p. 21. (2) OJ L 301, 24.11.1999, p. 6. (3) OJ L 224, 18.8.1990, p. 19. (4) OJ L 160, 26.6.1999, p. 103. (5) OJ L 315, 26.11.1985, p. 11. (6) OJ L 280, 13.11.1993, p. 33. (7) OJ L 33, 8.2.2000, p. 21. (8) OJ L 148, 6.6.1997, p. 27. (9) OJ L 30, 4.2.2000, p. 35. (10) OJ L 238, 22.9.2000, p. 61.

Supplementary provisions

ANNEX ISupplementary provisions

"ANNEX I Quantities and sub-types of antigen to be held in the antigen banks Potent well-tested vaccine strains corresponding to: >TABLE> The above strains shall be kept in quantities sufficient to carry out an emergency vaccination taking into account the estimated risks the different subtypes present to the Community livestock and in any case not less than two million doses of each subtype. Each dose of vaccine reconstituted from the above antigen should have an observed potency of 6 PD50 in cattle, when tested according to the European Pharmacopoeia." ANNEX II "ANNEX >TABLE>"

Source: EUR-Lex (Publications Office of the EU), Β© European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next